CompletedPhase 2NCT00936546
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
Studying Eosinophilic fasciitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Ghent
- Principal Investigator
- Filip De Keyser, MD, PhDUniversity Hospital, Ghent
- Intervention
- Rituximab(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2015
Study locations (1)
- University Hospital Ghent, Ghent, Belgium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00936546 on ClinicalTrials.govOther trials for Eosinophilic fasciitis
Additional recruiting or active studies for the same condition.